{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dolutegravir+%28DTG%29+AND+Tenofovir+alafenamide+%28TAF%29&page=2",
    "query": {
      "intervention": "Dolutegravir (DTG) AND Tenofovir alafenamide (TAF)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 36,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dolutegravir+%28DTG%29+AND+Tenofovir+alafenamide+%28TAF%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dolutegravir+%28DTG%29+AND+Tenofovir+alafenamide+%28TAF%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T01:56:35.928Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00042289",
      "title": "Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "atazanavir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #3",
          "type": "DRUG"
        },
        {
          "name": "elvitegravir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "tenofovir alafenamide fumarate (TAF)",
          "type": "DRUG"
        },
        {
          "name": "TAF w/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "TAF w/cobicistat or ritonavir",
          "type": "DRUG"
        },
        {
          "name": "efavirenz",
          "type": "DRUG"
        },
        {
          "name": "darunavir/cobicistat",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir/tenofovir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "rifampicin",
          "type": "DRUG"
        },
        {
          "name": "ethambutol",
          "type": "DRUG"
        },
        {
          "name": "isoniazid",
          "type": "DRUG"
        },
        {
          "name": "pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "kanamycin",
          "type": "DRUG"
        },
        {
          "name": "amikacin",
          "type": "DRUG"
        },
        {
          "name": "capreomycin",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "levoflaxacin",
          "type": "DRUG"
        },
        {
          "name": "ofloxacin",
          "type": "DRUG"
        },
        {
          "name": "ethionamide/prothionamide",
          "type": "DRUG"
        },
        {
          "name": "terizidone/cycloserine",
          "type": "DRUG"
        },
        {
          "name": "para-aminosalicylic acid (PAS)",
          "type": "DRUG"
        },
        {
          "name": "high dose INH",
          "type": "DRUG"
        },
        {
          "name": "bedaquiline",
          "type": "DRUG"
        },
        {
          "name": "clofazamine",
          "type": "DRUG"
        },
        {
          "name": "delamanid",
          "type": "DRUG"
        },
        {
          "name": "linezolid",
          "type": "DRUG"
        },
        {
          "name": "pretomanid",
          "type": "DRUG"
        },
        {
          "name": "ethinyl estradiol",
          "type": "DRUG"
        },
        {
          "name": "etonogestrel implant",
          "type": "DRUG"
        },
        {
          "name": "nevirapine",
          "type": "DRUG"
        },
        {
          "name": "amprenavir",
          "type": "DRUG"
        },
        {
          "name": "abacavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "indinavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "fosamprenavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #3",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "didanosine delayed release (Videx® EC)",
          "type": "DRUG"
        },
        {
          "name": "emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "tenofovir",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir dosage #1",
          "type": "DRUG"
        },
        {
          "name": "tipranavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir dosage #4",
          "type": "DRUG"
        },
        {
          "name": "raltegravir",
          "type": "DRUG"
        },
        {
          "name": "etravirine",
          "type": "DRUG"
        },
        {
          "name": "maraviroc",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "tenofovir/atazanavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "nelfinavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "indinavir/ritonavir dosage #2",
          "type": "DRUG"
        },
        {
          "name": "rilpivirine",
          "type": "DRUG"
        },
        {
          "name": "darunavir/ritonavir dosage #4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1578,
      "start_date": "2003-06-09",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-10-11T01:56:35.928Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042289"
    },
    {
      "nct_id": "NCT03631732",
      "title": "Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "NRTIs",
          "type": "DRUG"
        },
        {
          "name": "Third Agent",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 496,
      "start_date": "2018-08-28",
      "completion_date": "2020-08-19",
      "has_results": true,
      "last_update_posted_date": "2021-09-05",
      "last_synced_at": "2026-10-11T01:56:35.928Z",
      "location_count": 82,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03631732"
    },
    {
      "nct_id": "NCT02607930",
      "title": "Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "ABC/DTG/3TC",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "ABC/DTG/3TC Placebo",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 631,
      "start_date": "2015-11-13",
      "completion_date": "2021-07-02",
      "has_results": true,
      "last_update_posted_date": "2022-03-02",
      "last_synced_at": "2026-10-11T01:56:35.928Z",
      "location_count": 78,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02607930"
    },
    {
      "nct_id": "NCT02121795",
      "title": "Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        },
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Allowed third antiretroviral agent",
          "type": "DRUG"
        },
        {
          "name": "FTC/TDF Placebo",
          "type": "DRUG"
        },
        {
          "name": "F/TAF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 668,
      "start_date": "2014-05-06",
      "completion_date": "2019-03-01",
      "has_results": true,
      "last_update_posted_date": "2020-03-12",
      "last_synced_at": "2026-10-11T01:56:35.928Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02121795"
    },
    {
      "nct_id": "NCT04442737",
      "title": "A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "D/C/F/TAF FDC",
          "type": "DRUG"
        },
        {
          "name": "TAF/FTC FDC",
          "type": "DRUG"
        },
        {
          "name": "INI Based Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2020-07-01",
      "completion_date": "2023-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-10-11T01:56:35.928Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04442737"
    },
    {
      "nct_id": "NCT02285114",
      "title": "Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "3rd ARV agent",
          "type": "DRUG"
        },
        {
          "name": "Boosted PIs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-01-20",
      "completion_date": "2024-12-11",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-10-11T01:56:35.928Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02285114"
    },
    {
      "nct_id": "NCT07683000",
      "title": "Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Lenacapavir",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir Tablet",
          "type": "DRUG"
        },
        {
          "name": "Teropavimab",
          "type": "DRUG"
        },
        {
          "name": "Zinlirvimab",
          "type": "DRUG"
        },
        {
          "name": "SBR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 590,
      "start_date": "2026-07-14",
      "completion_date": "2033-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-11T01:56:35.928Z",
      "location_count": 2,
      "location_summary": "Berkeley, Michigan • Annandale, Virginia",
      "locations": [
        {
          "city": "Berkeley",
          "state": "Michigan"
        },
        {
          "city": "Annandale",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07683000"
    },
    {
      "nct_id": "NCT07532304",
      "title": "A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Bictegravir/emtricitabine/tenofovir alafenamide",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "MK4646",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 16,
      "start_date": "2026-05-11",
      "completion_date": "2026-07-23",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-11T01:56:35.928Z",
      "location_count": 1,
      "location_summary": "Anniston, Alabama",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07532304"
    },
    {
      "nct_id": "NCT03656783",
      "title": "Effects of Biktarvy on CFR in Stable HIV Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Biktarvy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 25,
      "start_date": "2018-09-14",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2023-02-08",
      "last_synced_at": "2026-10-11T01:56:35.928Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03656783"
    },
    {
      "nct_id": "NCT05652478",
      "title": "Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteer",
        "Weight Gain",
        "Metabolic Effects",
        "Integrase Strand Transfer Inhibitors"
      ],
      "interventions": [
        {
          "name": "Dolutegravir (DTG) AND Tenofovir alafenamide (TAF)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir Disoproxil Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir alafenamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2026-09-24",
      "completion_date": "2030-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-11T01:56:35.928Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05652478"
    }
  ]
}